Podcasts about diabetes and endocrinology

Host: Jennifer Caudle, DO Guest: Johanna Finkle, MD, FACOG As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

We welcome Dr. Tanya Thompson-Badamos, an endocrinologist with St. Peter's Diabetes and Endocrine Care.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

CME credits: 1.00 Valid until: 02-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-latest-in-stroke-risk-reduction-strategies-are-your-patients-protected/35860/ Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides=

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/adherence-to-insulin-therapies-real-world-evidence/29897/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-patient-centered-approach-to-diabetes-management/29903/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/key-considerations-of-once-weekly-basal-insulin-in-clinical-practice/29902/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/once-weekly-basal-insulins-starting-and-titrating/29901/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/redefining-convenience-clinical-outcomes-of-once-weekly-basal-insulins/29900/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-once-weekly-basal-insulins-work/29899/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/complications-and-hospitalizations-in-patients-with-t2d/29898/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-experience-what-its-like-to-be-living-with-daily-insulin-injections/29896/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/defining-stable-glycemic-control/29895/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

CME credits: 1.04 Valid until: 01-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/insulin-therapy-initiation-titration-and-monitoring/29894/ This educational program consists of 10 presentations on once-weekly basal insulin. Use of daily basal insulins can be a burden and therefore result in decline or delay in initiation or discontinuation of insulin therapy in patients with type 2 diabetes. It would be beneficial to explore the development of more effective and simpler regimens that could support patients in extending their insulin therapy over a longer period of time. Recently, trial data on once-weekly basal insulins have been published and one of the once-weekly formulations, insulin icodec, has been approved by the EMA and in other countries including Canada and Switzerland. Join three experts in their discussions about the challenges related to use of once-daily basal insulins and how once-weekly basal insulins might be a helpful solution.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it's essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: Ian de Boer, MD Since up to 40 percent of patients with diabetes develop diabetic kidney disease, it's essential to know how to proactively diagnose and treat them using the latest therapeutic advances and strategies. Tune in to hear Dr. Mary Katherine Cheeley discuss diabetes management in patients with chronic kidney disease with Dr. Ian de Boer, Professor of Medicine in the Division of Nephrology and the Director of the Kidney Research Institute at the University of Washington in Seattle.

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

Guest: Elena Toschi, MD Approximately over the last decade, lifespans in the general population have increased, along with a rise in the prevalence of type 1 diabetes in older adult patients. Since each patient has a unique disease, the clinician should personalize and devise the best approach to diabetes management and glycemic targets, as well as manage comorbidities and complications. To learn more, join Dr. Elena Toschi, Director of the Young Adult Program at Joslin Diabetes Center and Assistant Professor of Medicine at Harvard Medical School.

CME credits: 0.75 Valid until: 20-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/plozasiran-aro-apoc3-decreases-apoc3-and-triglycerides-tg-in-patients-with-mixed-hyperlipidemia-muir-final-results/24409/ This program brings you select scientific abstracts and late-breaking results from the recent American College of Cardiology 2024 Scientific Sessions. From clinical trials like PIONEER-AF and VOYAGER PAD to updates on the new guidelines, faculty experts are here to break down ways to advance cardiovascular care for all.

Host: John Buse, MD, PhD Guest: Kim Boggess, MD The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill.

Host: John Buse, MD, PhD Guest: Kim Boggess, MD The most common forms of diabetes encountered in pregnant patients include gestational diabetes and preexisting type 2 diabetes. So how does adding metformin to insulin treatment help these patients? Join Dr. John Buse as he talks about the MOMPOD Trial with lead author, Dr. Kim Boggess, Professor of Maternal Fetal Medicine at the University of North Carolina at Chapel Hill.

Guest: R. Paul Wadwa, M.D. Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Guest: R. Paul Wadwa, M.D. Since young kids have a different activity level and diet than older kids or adult patients, controlling type 1 diabetes in younger patients can be more challenging, and there tends to be more variability in their blood sugars. However, a recent study identified that hybrid closed-loop technology could help give children with type 1 diabetes the best outcomes and quality of life. To learn more, tune in with Dr. Paul Wadwa, Professor of Pediatrics and the Medical Director of the Pediatric Clinic at the Barbara Davis Center for Diabetes at University of Colorado Anschutz Medical Campus.

Host: Carol Wysham Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

Host: Carol Wysham, MD Guest: A. Michael Lincoff, MD Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.

Host: John Buse, MD, PhD Guest: Louis J. Aronne, MD, FTOS In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study's findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

Host: John Buse, MD, PhD Guest: Louis J. Aronne, MD, FTOS In the SURMOUNT-4 trial, 100 patients with obesity were on tirezpatide for 9 months, and the average weight loss was 20.9 percent. The patients were then randomized to receive either placebo with behavioral intervention or tirzepatide for another year, and the patients in the former group regained a significant amount of weight. Dive further into the study's findings and implications with Dr. John Buse and Dr. Louis Aronne, the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College in New York.

CME credits: 0.50 Valid until: 20-02-2025 Claim your CME credit at https://reachmd.com/programs/cme/revolutionizing-care-for-patients-with-t2d-and-obesity-from-pathophysiology-to-personalized-treatments/16467/ Embark on a transformative journey to redefine patient care for individuals with type 2 diabetes by transitioning from the conventional focus on glycemic control to a pioneering obesity-centered approach. Immerse yourself in the expertise of 3 distinguished professionals: Drs. Carol Wysham, Scott Kahan, and Ken Fujioka. These esteemed experts will guide you through the dynamic terrain of weight loss medications, including GLP-1/GIP dual receptor agonists, and provide invaluable insights to elevate and optimize patient outcomes in the realm of type 2 diabetes management. =

Host: John Buse, MD, PhD Guest: Mary de Groot, PhD The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Host: John Buse, MD, PhD Guest: Mary de Groot, PhD The prevalence of diabetes-related stigma is alarmingly high. In fact, four in five adults have reported experiencing some form of diabetes stigma at some point in their lives. To learn how we as healthcare providers can help reduce this burden for our patients with diabetes, Dr. John Buse speaks with Dr. Mary de Groot, Professor of Medicine and the Associate Vice Chair for Wellness at Indiana University School of Medicine.

Host: Stuart Weinzimer, MD The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients' quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD The artificial pancreas represents the integration of two separate devices: a continuous glucose monitor and an insulin pump. Learn more about this technology and how it can help improve diabetic patients' quality of life with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: Stuart Weinzimer, MD From continuous glocuose monitors to insulin pumps, there have been immense technological advancements for patients with type 1 diabetes. Learn more about how these two tools can be used to treat pediatric patients with type 1 diabetes with Dr. Stuart Weinzimer, Interim Section Chief of Pediatric Endocrinology and Diabetes at Yale School of Medicine.

Host: John Buse, MD, PhD Guest: Michael Fang, PhD According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study's key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.

Host: John Buse, MD, PhD Guest: Michael Fang, PhD According to a recent study published in the Annals of Internal Medicine, the median age of patients with type 1 diabetes is 24. However, type 1 diabetes that develops in adulthood is often mistakenly identified as type 2 diabetes, resulting in improper treatment. Joining Dr. John Buse to review this study's key findings and how we can determine if an adult with new-onset diabetes might have type 1 diabetes is Dr. Michael Fang, Assistant Professor in the Division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University.

Host: John Buse, MD, PhD Guest: Maria Jose Redondo, MD, PhD, MPH A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Host: John Buse, MD, PhD Guest: Maria Jose Redondo, MD, PhD, MPH A recent paper focused on a variety of topics associated with type 1 diabetes, including its heterogenenity, endotypes, slowly progressive insulin-dependent diabetes, and the term type 1.5 diabetes. Dive into these topics with Dr. John Buse and Dr. Maria Redondo, Professor of Pediatrics in the Division of Pediatric Diabetes and Endocrinology at Baylor College of Medicine in Texas.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: David Selzer, MD New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: David Selzer, MD New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Host: John Buse, MD, PhD Guest: Helen Murphy, PhD There are many challenges associated with managing type 1 diabetes (T1D) in pregnant patients, which is why a recent study examined the use of an automated insulin delivery system in this patient population. Using this method, insulin doses were adjusted every 8 to 10 minutes according to a patient's real-time glucose levels taken from her continuous glucose monitor. As a result, women experienced a higher percentage time in the pregnancy glucose target range, less hyperglycemia, and less gestational weight gain. Learn more about how these findings may impact the management of T1D both during and after pregnancy with Dr. John Buse and Dr. Helen Murphy, a Professor of Medicine in Diabetes and Antenatal Care at the University of East Anglia in the United Kingdom.

Host: John Buse, MD, PhD Guest: Helen Murphy, PhD There are many challenges associated with managing type 1 diabetes (T1D) in pregnant patients, which is why a recent study examined the use of an automated insulin delivery system in this patient population. Using this method, insulin doses were adjusted every 8 to 10 minutes according to a patient's real-time glucose levels taken from her continuous glucose monitor. As a result, women experienced a higher percentage time in the pregnancy glucose target range, less hyperglycemia, and less gestational weight gain. Learn more about how these findings may impact the management of T1D both during and after pregnancy with Dr. John Buse and Dr. Helen Murphy, a Professor of Medicine in Diabetes and Antenatal Care at the University of East Anglia in the United Kingdom.

Host: John Buse, MD, PhD Guest: Beth Pyatak, PhD, OTR/L According to a recent study, fluncuations in glucose levels while sleeping can directly impact type 1 diabetes patients' ability to complete daily activities. In fact, it was found that higher variability overnight led to lower sustained attention and lower engagement in demanding activities the following day. So how can we control glucose levels to help our patients feel better? Explore the study's key findings and management strategies with Dr. John Buse and Dr. Elizabeth Pyatak, an Associate Professor of Occupational Science and Occupational Therapy at the University of Southern California who worked on the study.

Host: John Buse, MD, PhD Guest: Beth Pyatak, PhD, OTR/L According to a recent study, fluncuations in glucose levels while sleeping can directly impact type 1 diabetes patients' ability to complete daily activities. In fact, it was found that higher variability overnight led to lower sustained attention and lower engagement in demanding activities the following day. So how can we control glucose levels to help our patients feel better? Explore the study's key findings and management strategies with Dr. John Buse and Dr. Elizabeth Pyatak, an Associate Professor of Occupational Science and Occupational Therapy at the University of Southern California who worked on the study.

Host: John Buse, MD, PhD Guest: Simon Heller, MD Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they'll review Dr. Heller's recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: John Buse, MD, PhD Guest: Simon Heller, MD Amid the crisis around the cost of diabetes care worldwide, biosimilar insulins could help save millions of dollars and allow more patients to be treated safely and effectively. But how exactly are these products approved, and how do they compare to the original product? Find out with Dr. John Buse and Dr. Simon Heller, Professor of Clinical Diabetes at the University of Sheffield and the Director of Research and Development at Sheffield Teaching Hospitals Foundation Trust in the United Kingdom. Together, they'll review Dr. Heller's recent paper on biosimilar basal insulins that was published in Clinical Diabetes.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Charlton, MD Liver disease is highly prevalent in patients with type 2 diabetes, and it's much more likely to be a clinically significant issue in these patients as well. So it's important to evaluate patients for liver disease during routine check-ups. Dive further into the effects of liver disease in diabetic care with Dr. Peter Buch as he speaks with Dr. Michael Charlton, Professor of Medicine and Co-Director of the Transplant Institute at the University of Chicago.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Charlton, MBBS Liver disease is highly prevalent in patients with type 2 diabetes, and it's much more likely to be a clinically significant issue in these patients as well. So it's important to evaluate patients for liver disease during routine check-ups. Dive further into the effects of liver disease in diabetic care with Dr. Peter Buch as he speaks with Dr. Michael Charlton, Professor of Medicine and Co-Director of the Transplant Institute at the University of Chicago.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Suijit Janardhan, MD, PhD Diabetic patients have a significant risk for developing more advanced liver disease, and the disease that they're particularly at risk for is steatotic liver disease. Dive into this episode to learn more with Dr. Charles Turck and Dr. Sujit Janardhan, Assistant Professor in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, and the Department of Transplant Surgery at Rush University Medical Center in Chicago.